Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Royalderm Agnieszka Nawrocka

Research site

Poland ul. Krzysztofa Kieślowskiego 3B/3, 02-962 Warsaw, Poland

  • 1 trial recruiting
  • Chronic spontaneous urticaria · Dermatitis atopic · Neurodermatitis
  • Adult patients

About Specializations

Royalderm Agnieszka Nawrocka in Warsaw, Poland specialises in clinical trials of conditions such as Chronic spontaneous urticaria, Dermatitis atopic, Neurodermatitis, Psoriasis, and other specialisations. This site conducts important research.

Main research areas of the site

Skin and Connective Tissue Diseases

The research at Royalderm Agnieszka Nawrocka evaluates innovative biologic therapies for inflammatory skin conditions, comparing their effectiveness and safety with existing standards.

  • Plaque psoriasis
  • Moderate to severe atopic dermatitis
  • Chronic spontaneous urticaria

Studies aim to demonstrate therapeutic equivalence, achieve high response rates, and assess long‑term disease control for patients in Warsaw.

Immune System Phenomena

Investigations target the underlying immune mechanisms that drive skin and connective‑tissue disorders, seeking to refine treatment strategies and predict disease progression.

  • Immune system modulation in dermatology
  • Evaluation of treatment durability
  • Biomarker development for response prediction

The work supports the development of next‑generation therapies and enhances understanding of immune‑driven skin disease.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
ul. Krzysztofa Kieślowskiego 3B/302-962 WarsawPoland
Open in maps ↗
Recruiting now
1 trial
Conditions studied
4

More sites in WarsawPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

4 clinical trials

Chronic spontaneous urticaria

Recruiting

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Psoriasis

Not recruiting

Study Comparing CT-P55 and Secukinumab for Moderate to Severe Plaque Psoriasis Patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Celltrion Inc.

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Neurodermatitis

Not recruiting

Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.